Interesting to think that technically everything is out of NWBO’s hands right now except a sign off for sending the MAA. I would think that any negotiations with NWBO for new clinical trial purposes might depend on creating the vaccine with an approved commercial scale process that is what everyone wants to keep costs down so combo pricing isn’t affected as much for partner products during reimbursement of future approved treatments and patient access. Are we there yet?; ). Best wishes.
Market Data 
Markets 
AI
